 | |
| Clinical data | |
|---|---|
| Other names | GW679769; GW-679769; (2R,4S)-4-(4-Acetylpiperazin-1-yl)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C30H35F7N4O2 |
| Molar mass | 616.625 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Casopitant (INNTooltip International Nonproprietary Name),[1]: 208 former tentative trade namesRezonic (U.S.) andZunrisa (Europe), is anNK1 receptor antagonist which was undergoing research for the treatment ofchemotherapy-induced nausea and vomiting.[2][3] It was under development byGlaxoSmithKline.[2] In July 2008, the company filed a marketing authorisation application with theEuropean Medicines Agency. The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary.[2][4] However, a 2022 review listed casopitant as under development as a potential novelantidepressant for the treatment ofmajor depressive disorder, with aphase 2clinical trial having been completed.[5]
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
